Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 9926315

Triazolopyridine compounds and methods for the treatment of cystic fibrosis

Flatley Discovery Lab, LLC · Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9920378

Allogeneic autophagosome-enriched composition for the treatment of disease

Providence Health & Services—Oregon · Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9919058

Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9918968

Rapamycin analogs targeting proteasome function in the treatment of cancer

The Board of Regents of the University of Texas System · Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9913841

6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive ai

Sulfateq B.V. · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9902769

Treatment of dermatological pathologies

XBIOTECH INC. · Granted Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9901619

Compositions comprising PEDF and uses of same in the treatment and prevention of ovary-rel

The Fund for Medical Research, Development of Infrastructure and Health Services—Assaf HaRofeh Medical Center · Granted Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9901580

Methods of eye treatment using therapeutic compositions containing dipyridamole

O.D. Ocular Discovery Ltd. · Granted Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9896532

Deactivation of urushiol and method of treatment and prevention of contact dermatitis

The Regents of the University of California · Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9896445

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

Ansana BioSciences, LLC · Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9895413

Protection against and treatment of ionizing radiation

The Board of Regents of the University of Texas System · Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9890379

Treatment of genetic disorders associated with DNA repeat instability

BIOMARIN TECHNOLOGIES B.V. · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9890213

Methods for the treatment of B cell-mediated inflammatory diseases

VACCINEX, INC. · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884096

Compositions and methods related to graft versus host disease and treatments thereof

The Regents of the University of Colorado, a Body Corporate · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878993

DNA-PK inhibitors for treatment of cancer

Vertex Pharmaceuticals Incorporated · Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878033

Immunogenic peptides for treatment of herpes simplex virus infection and conditions

The Regents of the University of California · Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878006

Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 pot

The Regents of the University of California · Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9877990

Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

Krystal Biotech, Inc. · Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9873876

Cancer treatment

Ionis Pharmaceuticals, Inc. · Granted Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9872909

Method for enhancing specific immunotherapies in cancer treatment

Providence Health & Services—Oregon · Granted Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9868954

Reduction of TGFβ signaling in myeloid cells in the treatment of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9868725

Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric m

Takeda Pharmaceutical Company Limited · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9867830

Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydr

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9867778

Controlled release antimicrobial compositions and methods for the treatment of otic disord

The Regents of the University of California · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted